Dennis E. Marshall - Jun 30, 2025 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Role
Director
Signature
/s/ John R. Browning, attorney-in-fact
Stock symbol
BLGO
Transactions as of
Jun 30, 2025
Transactions value $
$0
Form type
4
Date filed
7/2/2025, 05:10 PM
Previous filing
Jan 3, 2025
Next filing
Oct 2, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Marshall Dennis E Director 14921 CHESTNUT ST., WESTMINSTER /s/ John R. Browning, attorney-in-fact 2025-07-02 0001361115

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLGO Option to Purchase Common Stock Award +19K +0.4% 4.72M Jun 30, 2025 Common Stock 19K $0.20 Direct F1, F2
transaction BLGO Option to Purchase Common Stock Award +113K +2.42% 4.77M Jun 30, 2025 Common Stock 113K $0.20 Direct F3, F4
transaction BLGO Option to Purchase Common Stock Award +93.8K +1.97% 4.86M Jun 30, 2025 Common Stock 93.8K $0.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was granted to Reporting Person to replace an option to purchase 10,000 shares that had been issued to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
F2 Total reflects the expiration of options to purchase 10,000 shares that recently expired.
F3 This Option was granted to Reporting Person to replace an option to purchase 64,286 shares that had been issued to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee
F4 Total reflects the expiration of options to purchase 64,286 shares that recently expired.
F5 This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.